Nitrates have been widely used as anti-ischemic drugs in patients with vasospastic angina (VSA). However, the effect of long-term nitrate treatment on cardiac events in VSA patients remains unclear.
itrates have been widely used in the management of cardiovascular diseases, including vasospastic angina (VSA). 1 The major clinical limitation of nitrates is the rapid loss of their hemodynamic and anti-ischemic effects during long-term treatment; a phenomenon termed tolerance. The mechanisms underlying this nitrate tolerance might be multifactorial and might involve neurohormonal adjustments, as activation of the renin-angiotensin-aldosterone axis, as well as intrinsic changes to the vasculature itself. 2, 3 Calcium channel blockers (CCBs) are highly effective in suppressing coronary spasms and are widely used in patients with VSA. 1 Epidemiological studies have shown that being refractory to CCBs treatment, active smoking, ventricular arrhythmias during anginal attacks, reduced left ventricular ejection fraction (LVEF) and the presence of organic coronary stenosis are independent predictors of a poor outcome in patients with VSA. 4-6 However, the effect of long-term nitrate treatment on cardiac events in patients with VSA remains unclear. In the present study, we investigated whether the long-term use of nitrate was beneficial for reducing the incidence of cardiac events in patients with VSA who were treated with CCBs.
Methods

Study Population
This study enrolled 245 consecutive patients with VSA who were admitted to the Tama-Nagayama Hospital, Nippon Medical School between January 1998 and December 2003.
All eligible patients with VSA underwent coronary angiography (CAG) because of chest pain at rest or on exertion associated with an ST segment elevation of 1.0 mm or more, or depression of 1.0 mm or more in at least 2 contiguous leads on the 12-lead electrocardiogram (ECG) or Holter recording without elevated cardiac enzymes. A temporary pacing catheter was inserted into the right ventricle apex via the femoral vein after a control CAG, and was set with a backup pacing at a rate of 50 beats/min. All subjects had normal coronary Nitrate Treatment in VSA angiograms and showed angiographically documented coronary spasms after intracoronary administration of acetylcholine (ACh). Incremental doses of ACh were injected into the left coronary artery (20, 50 and 100 μg) and the right coronary artery (20 and 50 μg) until ACh induced coronary spasms. Intracoronary nitroglycerin (NTG) was administered when ACh-induced coronary spasms did not resolve spontaneously within 5 min, or chest pain persisted for more than 2 min, and the ACh provocation test was completed. A coronary spasm was defined as a transient, total or subtotal occlusion (≥90% stenosis) of a coronary artery associated with both chest pain and myocardial ischemic ST segment changes on ECG. Multivessel spasms were defined as documented coronary spasms induced by an ACh provocation test in at least 2 major coronary arteries associated with chest pains, which was the same as that of spontaneous anginal attacks and myocardial ischemic ST segment changes on ECG. The diagnostic criterion of variant angina was typical chest pain at rest, particularly between night and early morning with a significant ST-segment elevation.
All patients with clinical signs of acute infection, autoimmune disorders, severe renal (serum creatinine level >2.0 mg/dl) or hepatic disease or with a suspected malignancy were excluded. The investigation protocol was designed according to the guidelines of the institutional ethics committee. All patients provided their written informed consent to participate in the study.
Study Protocol
This study was a prospective cohort study, and a total of 245 consecutive eligible patients with VSA (153 males and 77 females; mean age, 60±10 years) who had a positive response to the ACh provocation test were enrolled in the present study. None of the patients had received any anti-ischemic drugs, including CCBs, nitrates, nicorandil, or any combination of these medications prior to enrollment. All patients were treated with CCBs after enrollment: amlodipine 5-10 mg/day, diltiazem 100-200 mg/day, nifedipine 20-40 mg/day, benidipine 4-8 mg/day or manidipine 10 mg/day. When angina was refractory or adverse effects developed, other CCBs or medications, including nitrates or nicorandil, were prescribed.
The angina refractory response to CCBs was defined as follows: ST segment depression (≥1.0 mm) or elevation (≥1.0 mm) with or without chest pain during the 24 h Holter recording under the use of CCBs. Ninety-two patients received nitrates (nitrate group), and 153 patients did not receive nitrates (without nitrate group). All physicians obtained coronary angiographic and left ventriculographic (LVG) findings, including LVEF, the prevalence of total occlusion and multivessel spasms after ACh provocation, and the clinical characteristics, including the frequency of chest pain at rest within 48 h before admission (pre-angina, unstable angina [UA] on admission). Next, each physician chose anti-ischemic drugs, including CCBs, nicorandil, nitrates and any combination of these medications. The choice of CCBs and use of nitrates were determined by the patients' individual physician; the use of nitrates was not assigned in a randomized manner. Four patients were excluded from the nitrate group, and 5 patients were excluded from the without nitrate group because they had hypotension, and 2 and 3 patients from each group, respectively, were excluded from the study because of liver function disturbance due to CCBs. Therefore, 86 patients in the nitrate group and 145 patients in the without nitrate group were included in the analyses. In patients treated with nitrates, 27 patients continuously received long-acting oral isosorbide dinitrate (ISDN-R; 40 mg/day) and 41 patients continuously received oral isosorbide mononitrate (ISMN; 40 mg/day) without a dose-free interval, and 18 patients received long-acting transdermal NTG (Trans NTG; 25 mg/day) with a dose-free interval (intermittent transdermal NTG treatment).
The risk factors included: smoking, at least 1 cigarette per day for one or more years, and this was classified as active smoking; hypertension, systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or having received antihypertensive medication; diabetes, fasting plasma glucose ≥126 mg/dl, a casual plasma glucose ≥200 mg/dl or 2 h plasma glucose during a 75-g oral glucose tolerance test ≥200 mg/dl or having received antidiabetic medication; dyslipidemia, an overnight fasting serum total cholesterol ≥220 mg/dl, triglycerides (TG) ≥150 mg/dl, low-density lipoprotein cholesterol (LDL-C) ≥140 mg/dl, or high-density lipoprotein cholesterol (HDL-C) <40 mg/dl, or taking any lipid-moderating medications before enrollment in this study. The LDL-C was calculated by using the Friedwald formula. Only patients with dyslipidemia were treated with 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). The estimated glomerular filtration rate (eGFR) was calculated from the new Japanese equation: eGFR (ml · min -1 · 1.73 m -2 ) =194 × Age -0.287 × Serum-creatinine -1.094 (if female × 0.739). 7 The CAG findings were analyzed by 2 independent cardiologists without any knowledge of the patients' clinical characteristics, and the LVEF was calculated from the LVG.
Follow-up Data
The patients were followed-up with a median follow-up period of 70.5 months (range: from 4.8 to 140.0 months). As mentioned above, 6 patients were excluded from the nitrate group and 9 patients were excluded from the without nitrate group during the course of treatment. Therefore, 86 patients in the nitrate group and 145 patients in the without nitrate group were included in the analyses. Cardiac events were defined as sudden cardiac death and re-admission for acute coronary syndrome (ACS; acute myocardial infarction [AMI] and UA). The definition of AMI was persistent chest pain for >20 min, an ST segment elevation of ≥2.0 mm on at least 2 contiguous ECG leads, the development of pathological Q waves and an increase in the serum creatine kinase (CK) levels above twice the upper limit of the normal range. UA was defined according to the Braunwald classification 8 as angina at rest within the preceding 48 h, with either ST segment depression (≥1.0 mm) or T-wave inversion in 2 or more contiguous leads on the presenting ECG and serum CK levels within the normal range.
Statistical Analysis
The results are presented as mean values ± SD for continuous variables and as percentages of the total number of patients for categorical variables. The Student's t-test for independent samples and the chi-square test were used for comparisons of the continuous and categorical variables, respectively. The C-reactive protein (CRP) and TG levels were not normally distributed, and therefore the data are expressed as the median (25 th -75 th percentile); the Mann-Whitney U test was used for unpaired comparisons between the 2 groups, and the Wilcoxon's signed rank test was used for paired comparisons within the 2 groups. To determine the cut-off values for age, the white blood cell (WBC) count and CRP, HDL-C and TG levels as predictors of cardiac events, receiver-operating characteristic (ROC) curve analysis was performed. In addition, the area under the ROC curve with a 95% confidence interval (CI) was calculated and described in the figures KOSUGI M et al.
and text. Kaplan-Meier survival curves were used in the groups of patients with or without nitrates, and the log-rank test was used to compare the groups. Univariate and multivariate Cox hazards analyses were used to calculate the estimated hazard ratio (HR) with the 95%CI, where appropriate. The variables were entered into a multivariate model when a P value ≤0.2 was obtained by univariate analysis; the variables were: the patients age, having a refractory response to CCBs, variant angina, ventricular tachycardia (VT) or ventricular fibrillation (VF) during anginal attacks, active smoking, total occlusion after ACh provocation, LVEF ≤50%, WBC count on admission ≥6,800 /mm 3 , eGFR 60≤ml · min -1 · 1.73 m -2 , TG ≥140 mg/dl, HDL-C ≤45 mg/dl, and the use of nitrates, nicorandil and statins, and the presence of hypertension and pre-angina (UA on admission). The Statistical Package for Social Science (SPSS) for Windows software package, version 17.0 (Chicago, IL, USA), was used for all statistical analyses. A P value <0.05 was considered to be statistically significant.
Results
Patient Characteristics
The baseline clinical characteristics of the 86 patients with nitrates and 145 without nitrates are shown in Table 1 . The patients taking nitrates showed significantly lower serum TG and eGFR levels in comparison to those without nitrates. The heart rate tended to be higher in patients with nitrates than in those without nitrates. However, the overall clinical characteristics were generally similar between the groups at baseline.
The baseline CAG and LVG findings, clinical characteristics and the prevalence of the medications in the patients with nitrates and those without nitrates are shown in Table 2 . The frequency of chest pain at rest within 48 h (pre-angina, UA on admission) and variant angina prior to enrollment in the present study, total occlusion and multivessel spasms after ACh provocation, LVEF, and the prevalence of active smoking, were comparable between the groups. In addition, the ratios of the current medications were generally similar between the groups except for the prevalence of nicorandil and a combination of 2 CCBs (combination of CCBs) ( Table 2) .
Relationships Between Clinical Characteristics and Cardiac Events
During a median follow-up period of 70.5 months (range: 4.8-140.0 months), 29 patients developed cardiac events, including 7 sudden cardiac deaths and 22 re-admission due to ACS ( Table 2) .
In the patients with ACS, 2 had an AMI and 20 patients had UA ( Table 2 ). An emergency CAG showed that 19 patients had normal CAG, and 2 patients had 1 vessel disease and the remaining 1 patient had triple vessel disease, therefore, 2 patients received emergency percutaneous coronary intervention and 1 patient received elective coronary artery bypass grafting after admission.
In the 7 patients with sudden cardiac death, all patients had been documented to have VT or VF during anginal attacks prior to enrollment in the present study. Of the 7 patients, 4 patients, including 3 patients diagnosed with Brugada syndrome, had received implantable cardioverter-defibrillators (ICDs) because VT or VF was easily induced during an electrophysiological study ( Table 2 ). In addition, ICD was also implanted in 1 patient who had VF during anginal attacks. Despite the ICD implantation, 3 patients, including 2 patients with Brugada syndrome, died suddenly due to VF ( Table 2) . The remaining 2 patients experienced sudden death due to VF documented by 24 h ECG recordings, despite continuous intravenous NTG treatment. In addition, the remaining patient suddenly died at home, probably due to VT or VF. One patient with Brugada syndrome who received an ICD is still alive at the time of writing this manuscript. The clinical characteristics of patients with cardiac events and those without events are shown in Table 3 . Patients with cardiac events were older and showed a significantly higher prevalence of active smoking, and had a higher WBC count and, CRP level on admission, and a lower eGFR at discharge in comparison to those without cardiac events. The high-density lipoprotein (HDL)-cholesterol and TG levels in patients with cardiac events were lower than in those without events.
Relationships Among CAG and LVG Findings, Medications, and Cardiac Events
The CAG and LVG findings, and the medications for patients with cardiac events and those without events are shown in Table 4 . Refractory response to CCBs, pre-angina (UA on admission) and total coronary occlusion after ACh provocation were more frequently observed in patients with cardiac events than in those without events.
Three patients discontinued amlodipine treatment because Data are expressed as the mean ± SD or medians (plus inter quartile ranges). Abbreviations see in Table 1 . KOSUGI M et al.
their angina had a refractory response to medications; therefore, those 3 patients received diltiazem. However, the remaining 228 patients have been receiving the same medications during the entire follow-up period ( Tables 2,4) . Patients with cardiac events showed a higher prevalence of nitrates in comparison to those without events. However, the prevalence of CCBs and a combination of CCBs, nicorandil, statins and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) were comparable between the groups. Interestingly, patients with cardiac events were more likely to be receiving ISMN than those without events.
However, there were no significant differences in the prevalence of long-acting ISDN-R or intermittent transdermal NTG between patients with and without cardiac events. Table 2 . Figure 1 . Kaplan-Meier event-free curves and log-rank tests indicated that patients treated with nitrates had a significantly increased cardiac event rate during the follow-up period (log-rank 5.942, P=0.015). Nitrate Treatment in VSA log rank 5.942, P=0.015, Figure 1 ). In addition, cardiac events occurred in 11 of the 41 (26.9%) patients treated with ISMN and only 3 of the 27 patients (11.1%) treated with ISDN-R (log rank 5.071, P=0.024). However, the incidence of events was similar between patients treated with ISDN-R and those treated with transdermal NTG.
Effects of Long-Term Nitrate Treatment on Cardiac Events
Cardiac events occurred in 17 patients treated with nitrates, whereas only 1 patient treated with a combination of CCBs experienced a cardiac event during the follow-up period (24/86; 27.9% vs. 1/20; 5.0%, P=0.018). Receiver-operating characteristic (ROC) curves and the areas under the ROC curves (AUC) with 95% confidence intervals of C-reactive protein (CRP) and the white blood cell (WBC) count on admission (A), and high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) (B) for predicting cardiac events. KOSUGI M et al.
Effects of CCBs on Cardiac Events in Patients With VSA
The initial prevalence of CCBs is shown in Table 2 . Three patients treated with amlodipine experienced frequent chest pain in the outpatient clinic; therefore, these patients were treated with diltiazem. The final prevalence of CCBs is shown in Table 4 . The incidence of events in patients treated with amlodipine was slightly higher than in those treated with nifedipine, diltiazem and other CCBs [amlodipine; 7/34 (20.6%), nifedipine; 10/107 (9.4%), diltiazem; 11/102 (10.8%), other CCBs; 1/7 (14.2%)]; however, the differences did not reach statistical significance (log rank 6.815, P=0.078, Figure 2 ).
ROC Curve Analysis
ROC curve analysis revealed that the best cut-off values for the age of patients, plasma CRP levels and WBC count on admission ( Figure 3A) , and TG and HDL-C levels ( Figure 3B ) for predicting cardiac events were: 60 years, 6,800 /mm 3 and 0.25 mg/dl (Figure 3A) , and 140 mg/dl and 45 mg/dl (Figure 3B) , respectively. The sensitivities and specificities for the age of patients, plasma CRP levels and WBC count on admission to predict cardiac events were assessed across a range of cut-off values. The best cut-off value for each parameter was obtained at sensitivities of 58.6%, 51.7% and 89.7% (Figure 3A) , and 57.9% and 55.4% (Figure 3B) , and specificities of 62.2%, 53.0% and 73.8% (Figure 3A) , and 65.5% and 65.5% (Figure 3B) , respectively.
Cox Proportional Hazards Analysis for Cardiac Events
The results of univariate and multivariate Cox proportional hazards analyses are shown in 
Discussion
Nitrates are metabolized to nitric oxide (NO) in the body, which in turn activates guanylate cyclase to increase cyclic GMP, resulting in relaxation of vascular smooth muscle. Nitrates also suppress the activity of Rho-kinase via NO and thereby relax the smooth muscle. 1 Therefore, nitrates have been one of the most widely used anti-ischemic drugs. Given acutely, nitrates are excellent agents for the treatment of stable effort angina, UA, AMI, chronic heart failure and VSA. 1,9,10 However, the long-term hemodynamic and anti-ischemic efficacies of nitrates are rapidly attenuated by the development of nitrate tolerance. The phenomenon of tolerance is characterized by impaired responsiveness to the organic nitrates, demonstrated by reduced nitrate-induced vasodilatation and a blunting of blood pressure-lowering effects. Nitrate-induced tolerance to other endothelium-dependent and independent vasodilators is termed cross-tolerance. 3
Effect of Nitrates on Cardiac Events in Patients With Coronary Artery Disease
Curfman et al 9 showed that intravenous NTG was effective in the management of ischemic episodes in patients with UA at an acute phase, whereas 2 large clinical trials demonstrated that oral or transdermal nitrates did not reduce short-term mortality in patients with AMI. 11, 12 In addition, 2 observational studies in Japan showed that long-term nitrate treatment did not reduce the incidence of cardiac events in patients with Tables 1,2 . Nitrate Treatment in VSA AMI. 13, 14 There have been scant studies regarding the relationship between long-term nitrate treatment and cardiac events in VSA patients. Therefore, we performed a prospective cohort study to investigate whether long-term nitrate treatment was beneficial for reducing the incidence of cardiac events in VSA patients. The present study demonstrated for the first time that long-term nitrate treatment did not reduce the incidence of cardiac events in VSA patients.
Prognostic Factors for the Long-Term Outcomes in Patients With Vasospastic Angina
Epidemiological studies have demonstrated that older age, a refractory response to CCBs treatment, low LVEF, the presence of significant coronary stenosis and active smoking status are independent predictors of cardiac events in VSA patients. 4-6 Recently, investigators have shown that insulin resistance, low-grade inflammation and oxidative stress play significant roles in the pathogenesis and instability of VSA.
15-18
The present study showed that long-term nitrate treatment, a refractory response to CCBs, pre-angina (UA on admission), patient age ≥60 years, CRP ≥0.25 mg/dl on admission (lowgrade inflammation), active smoking status, LVEF ≤50% (low LVEF), and eGFR ≤60 ml · min -1 · 1.73 m -2 (presence of chronic kidney disease) at discharge are independent predictors of poor outcomes in patients with VSA. The pathophysiological mechanisms underlying coronary spasms are still unknown. However, endothelial dysfunction through abnormalities of endothelial NO synthetase and enhanced contractility of vascular smooth muscle in coronary artery segments are considered to be major mechanisms in VSA. 18, 19 Recent studies have demonstrated that chronic administration of nitrates induces endothelial dysfunction. 20, 21 The present study showed that long-term nitrate treatment is significantly independently associated with cardiac events in VSA patients. Long-term nitrate treatment might cause nitrate tolerance, thus leading to subsequent endothelial dysfunction. Taken together, long-term nitrate treatment, associated with nitrate tolerance and endothelial dysfunction, might be a contributory factor in the poor outcomes of patients with VSA.
Long-Term Prognosis in Patients With Vasospastic Angina
The present study showed that cardiac events occurred in 29 of the 231 patients (12.6%) with VSA during the follow-up period. In addition, cardiac events were observed more frequently in patients treated with nitrates (17/86; 19.8%) than in those who were not taking nitrates (12/145; 8.3%). Ito et al 5 showed that cardiac events occurred in 54 of 527 patients (10.2%; 39 cardiac deaths and 15 non-fatal AMI), and Yasue et al 22 showed that 44 of the 245 patients (18.0%) developed cardiac events, including 12 cardiac deaths and 32 non-fatal AMI during the follow-up period. Therefore, the overall incidence of cardiac events in the present study was consistent with those in previous studies. 5, 22 However, the incidence of events in patients treated with nitrates in the present study was slightly higher than those reported in previous studies.
Mechanisms of Nitrate Tolerance in Patients With Cardiovascular Diseases
The mechanisms underlying nitrate tolerance appear to be multifactorial and might involve neurohormonal adjustments, such as activation of the renin-angiotensin-aldosterone axis, as well as changes intrinsic to the vasculature itself. 2, 3 Recent studies have shown that mitochondrial oxidative stress associated with aldehyde dehydrogenase (ALDH2) plays a central role in the development of nitrates tolerance. 3
Effect of Coronary Spasms on the Occurrence of AMI
AMI occurs in patients with VSA in the presence or absence of significant coronary stenosis. Saito et al 23 demonstrated that the presence of plaque without calcification detected by the intravascular ultrasound is related to the occurrence of coronary spasms, thus suggesting that coronary spasms are associated with mild atherosclerosis in the early stage and might induce vulnerable plaque as a precursor to AMI. Provoked coronary spasms predict adverse outcomes in AMI patients. 24 In addition, coronary spasms play a significant role in the progression of coronary atherosclerosis and subsequent AMI. 25 Therefore, coronary spasms play an important role in the pathogenesis of AMI.
These findings indicate that long-term nitrate treatment associated with tolerance and endothelial dysfunction might induce frequent vasospasms and play a significant role in the progression of atherosclerosis and subsequent AMI in VSA patients.
Effects of Medications on Cardiac Events in VSA Patients
CCBs are highly effective in suppressing coronary spasms in patients with VSA 1 . However, it remains unclear whether CCBs can reduce oxidative stress. The present study showed that there were no significant differences in cardiac events among the patients treated with amlodipine, nifedipine, diltiazem, or other CCBs (Figure 2) . Hirai et al 26 showed that an ARB suppressed the development of nitrate tolerance during transdermal NTG treatment. Statins (3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) reduce cardiovascular events and improve endothelial dysfunction. 27, 28 Recently, Yasue et al 29 demonstrated that fluvastatin reduced coronary spasms. However, the present study showed that use of ARBs, ACEIs and statins were not positive predictors of cardiac events in patients with VSA. Further studies might be necessary to clarify the efficacies of these medications on the longterm prognosis in VSA patients.
Physicians prescribe nitrates and/or nicorandil in addition to CCBs and a combination of CCBs when the spasms are severe. In our prospective cohort study, all physicians obtained the information about patient clinical characteristics, including the presence or absence of pre-angina (UA on admission) and variant angina, and CAG and LVG findings, including the LVEF, the prevalence of total occlusion and multivessel spasms after ACh provocation ( Table 2) , and each physician chose the anti-ischemic drugs for their patients, including CCBs, nicorandil, nitrates or a combination of these medications. At entry, there were no significant differences in the prevalence of medications, including CCBs, ACEIs, ARBs or statins between the patients treated with and without nitrates. However, unexpectedly, nicorandil and a combination of CCBs were more frequently prescribed in patients treated with nitrates in comparison to those treated without nitrates, despite the fact that the clinical characteristics and CAG and LVG findings were generally similar between the 2 groups ( Table 2) . Therefore, it is unknown why the physicians chose nicorandil or a combination of CCBs for the patients treated with nitrates.
We showed that 29 of our patients experienced cardiac events, including 7 sudden cardiac deaths and 22 re-admissions for ACS during a median follow-up period of 70.5 months. The prevalence of medications was comparable between the patients with and without cardiac events (Table 4) . However, nitrates were more frequently prescribed in patients KOSUGI M et al.
with cardiac events in comparison to those without events, although the background clinical characteristics, CAG and LVG findings were non-equivalent (Tables 3,4) . We also found that ISMN was more frequently prescribed in patients with cardiac events than to those without events. The intermittent transdermal NTG treatment was more effective for the prevention of tolerance in comparison to continuous NTG treatment in patients with stable coronary artery disease. 30 Ahlner et al 31 have shown that clinical signs of nitrate tolerance develop with long-term treatment with oral ISMN and ISDN, suggesting that tolerance development might be uniform to both ISMN and ISDN. However, a recent study showed that a once-daily therapy with ISMN caused greater endothelial dysfunction in comparison to placebo. Long-term ISMN treatment, even on a once-daily use, might therefore not be beneficial for preventing nitrate tolerance or preventing endothelial dysfunction. 21 CCBs are widely used medications in the management of VSA, and a recent guideline for the diagnosis and treatment of VSA recommended CCBs as first-line agents for VSA patients. 1 Short-acting nitrates are recommended only for sublingual administration, spraying in the oral cavity, or intravenous administration during an anginal attack. Administration of long-acting nitrates is recommended for the prevention of coronary spasms, and administration of nicorandil is also recommended for VSA, and are classified as Class IIa agents (as judged from available findings and opinions, thus indicating that they are a method of evaluation or treatment that is likely to be beneficial and effective). However, there were no comments in the guidelines regarding the relationship between long-term nitrate treatment and the development of nitrate tolerance.
In the present study, each physician prescribed medications based on their own experiences, and it was not always nitrates and/or nicorandil in addition to CBBs treatment using the guidelines and/or clinical characteristics, or CAG and LVG findings or other factors, such as frequency of chest pain prior to enrollment. We did not mention the information about the frequency of chest pain prior to enrollment, because such information is not always available from medical records.
Study Limitations
The most significant limitation of this study was that the sample data (number of participants) in this study were small. In addition, the use of nitrates was determined by the patients' individual physician and use was not assigned in a randomized manner. As a result, larger randomized clinical trials will be needed to confirm these results.
Conclusion
The current study demonstrated that long-term nitrate treatment in addition to CCBs did not reduce the incidence of cardiac events in patients with VSA. Further study will be needed to confirm the study findings and to clarify the pathophysiological mechanisms underlying these results.
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